Press Release Distribution and Management
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comI don’t have real-time access to news feeds in this moment. Here’s a quick summary of the most recent publicly reported items I found from reliable sources up to early 2025–2026, focused on entities named “Charm” across different sectors. If you had a specific Charm (company, product, person, etc.) in mind, tell me which one and I’ll tailor the update.
Latest highlights by sector
- Charm Security (AI-powered security startup)
- March 25, 2025: Emerged from stealth with an $8M seed round led by Team8’s Venture Creation Fund to fight scams and social engineering exploiting human vulnerabilities [PR Newswire, 2025-03-24 / 2025-03-25 snippet].[1]
- CHARM Therapeutics (biotech)
- 2024–2025: Series B financing around $80M, with NEA and SR One leading; appointment updates for senior leaders (e.g., Chief Medical Officer in Sept 2025) as the company advances AI-designed menin inhibitors for AML [Charm Therapeutics press releases and GlobeNewswire listings; 2024–2025 window].[2][3][6]
- 2025: Updates on CHM-029, a next-generation menin inhibitor advancing toward first-in-human studies; ongoing clinical development plans highlighted in 2025 press material [GlobeNewswire, 2025 entries].[3][6]
- Charm Communications, Charm Communications Inc. (advertising/communications)
- Ongoing coverage through market and press outlets through 2023–2024; public updates typically found in financial press and company pages (contextual reference rather than a single standout breaking news item in 2025).[9][10]
- Other “Charm” mentions (media, shows, or unrelated entities)
- Various entertainment and tech topics labeled “charms” or “Charm” in broader media coverage; not a single dominant breaking news item.
Illustrative example
- If you’re tracking Charm Therapeutics, the most significant recent developments are:
- The Series B funding around $80M and leadership hires in 2025 to push a clinical program (menin inhibitor for AML) forward.[3]
- The ongoing preclinical/clinical progression of CHM-029 with resistance mutations addressed, aiming for first-in-human trials.[6][3]
What I can do next
- Narrow to a specific Charm (e.g., Charm Therapeutics, Charm Security, or Charm Communications). I can pull the very latest headlines, summarize them, and provide direct links.
- If you want, I can also deliver a concise, sourced briefing with a one-paragraph summary per entity and a comparative quick-reference table (if you specify which Charms to include).